Abstract
Background: The importance of predicting human pharmacokinetics during compound selection has been recognized in the pharmaceutical industry. To this end there are many different approaches that are applied.
Methods: In this study we compared the accuracy of physiologically based pharmacokinetic (PBPK) methodologies implemented in GastroPlus™ with the one-compartment approach routinely used at Pfizer for human pharmacokinetic plasma concentration-time profile prediction. Twenty-one Pfizer compounds were selected based on the availability of relevant preclinical and clinical data. Intravenous and oral human simulations were performed for each compound. To understand any mispredictions, simulations were also performed using the observed clearance (CL) value as input into the model.
Results: The simulation results using PBPK were shown to be superior to those obtained via traditional one-compartment analyses. In many cases, this difference was statistically significant. Specifically, the results showed that the PBPK approach was able to accurately predict passive distribution and absorption processes. Some issues and limitations remain with respect to the prediction of CL and active transport processes and these need to be improved to further increase the utility of PBPK modelling. A particular advantage of the PBPK approach is its ability to accurately predict the multiphasic shape of the pharmacokinetic profiles for many of the compounds tested.
Conclusion: The results from this evaluation demonstrate the utility of PBPK methodology for the prediction of human pharmacokinetics. This methodology can be applied at different stages to enhance the understanding of the compounds in a particular chemical series, guide experiments, aid candidate selection and inform clinical trial design.
References
Dedrick RL. Animal scale-up. J Pharmacokinet Biopharm 1973; 1: 435–61
Boxenbaum H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 1982; 10: 201–27
Hosea NA, Collard WT, Cole S, et al. Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches. J Clin Pharmacol 2009; 49(5): 513–33
Rowland M, Balant L, Peck C. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report (Georgetown University, Washington, DC, May 29–30,2002). AAPS PharmSci 2004; 6: E6
Nestorov I. Whole body pharmacokinetic models. Clin Pharmacokinet 2003; 42: 883–908
Andersen ME. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol Letts 1995; 79: 35–44
Kawai R, Lemaire M, Steimer J-L, et al. Physiologically based pharmacokinetics study on a cyclosporine derivative, SDZ IMM 125. J Pharmacokin Biopharmac 1994; 22(5): 327–65
Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469–79
Howgate EM, Rowland Yeo K, Proctor NJ, et al. Prediction of in vivo drug clearance from in vitro data: I. Impact of interindividual variability. Xeno-biotica 2006; 36(6): 473–97
Poulin P, Theil FP. A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J Pharm Sci 2000; 89: 16–35
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 2002; 91: 129–56
Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs. J Pharm Sci 2001; 90: 436–47
Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 2004; 93(6): 1628–40
Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94: 1259–76
Rodgers T, Rowland M. Physiologically based pharmacokinetic modeling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95(6): 1238–57
Rodgers T, Rowland M. Mechanistic approaches to volume of distribution predictions: understanding the processes. Pharm Res 2007; 24(5): 918–33
Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 2001; 50 (Suppl. 1): S41–67
Willmann S, Schmitt W, Keldenich J, et al. A physiological model for the estimation of the fraction dose absorbed in humans. J Med Chem 2004; 47: 4022–31
Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies: II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci 2002; 91: 1358–70
Theil FP, Guentert TW, Haddad S, et al. Utility of physiologically based pharmacokinetic models to drug development and rational drug discovery candidate selection. Toxicol Lett 2003; 138: 29–49
Jones HM, Parrott N, Jorga K, et al. A novel strategy for physiologically based predictions of human pharmacokinetics. Clin Pharmacokinet 2006; 45(5): 511–42
De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007; 35(10): 1766–80
Peters SA. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis. Clin Pharmacokinet 2008; 47(4): 261–75
Lave T, Parrott N, Grimm HP, et al. Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 2007; 37(10): 1295–310
Leahy DE. Integrating in vitro ADMET data through generic physiologically based pharmacokinetic models. Expert Opin Drug Metab Toxicol 2006; 2(4): 619–28
Jamei M, Marciniak S, Feng K, et al. The Simcyp® population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5(2): 211–23
Brown RP, Delp MD, Lindstedt SL, et al. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 1997; 13: 407–84
Arundel PH. A multi-compartmental model generally applicable to physiologically-based pharmacokinetics (AstraZeneca, UK) [poster]. 3rd IFAC Symposium: Modelling and Control in Biomedical Systems; 1997 Mar 23–26; Warwick
Yu LX, Amidon GL. A compartmental absorption and transit model for estimating oral drug absorption. Int J Pharm 1999; 186: 119–25
Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharm Res 2005; 22: 103–12
Paine SW, Parker AJ, Gardiner P, et al. Prediction of the pharmacokinetics of atorvastatin, cerivastatin and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab Dispos 2008; 36: 1365–74
Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350–9
Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Disp 2007; 35: 293–301
McGinnity DF, Soars MG, Urbanowicz RA, et al. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Disp 2004; 32: 1247–53
Parrott N, Paquereau N, Coassolo P, et al. An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery. J Pharm Sci 2005; 94: 2327–43
Jones HM, Parrott N, Ohlenbusch G, et al. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modelling. Clin Pharmacokinet 2006; 45(12): 1213–26
Germani M, Crivori P, Rocchetti M, et al. Evaluation of a basic physiologically based pharmacokinetic model for simulating the first-time-in-animal study. Eur J Pharm Sci 2007; 31: 190–201
De Buck SS, Sinha VK, Fenu LA, et al. The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools. Drug Metab Disp 2007; 35: 649–59
Edginton AN, Theil FP, Schmitt W, et al. Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol 2008; 4(9): 1143–52
Acknowledgements
The authors would like to acknowledge the vast number of colleagues within Pfizer Worldwide R&D who provided the experimental and clinical data that were used in the analysis. No source of funding was used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jones, H.M., Gardner, I.B., Collard, W.T. et al. Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling. Clin Pharmacokinet 50, 331–347 (2011). https://doi.org/10.2165/11539680-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11539680-000000000-00000